Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

62.53
+0.50000.81%
Post-market: 59.41-3.1200-4.99%17:28 EDT
Volume:1.53M
Turnover:95.05M
Market Cap:12.10B
PE:644.47
High:62.87
Open:62.85
Low:61.37
Close:62.03
Loading ...

Incyte Exec Says Impact of Any Potential Tariffs on Pharmaceuticals to Be "Minimal" - Conf Call

THOMSON REUTERS
·
29 Apr

BUZZ-Incyte rises after beating quarterly results estimates

Reuters
·
29 Apr

Incyte raises 2025 sales forecast for blood cancer drug after solid quarter

Reuters
·
29 Apr

Incyte Shares up 5% Premarket After Co Beats Q1 Profit and Revenue Estimates

THOMSON REUTERS
·
29 Apr

Incyte Q1 Adjusted Earnings, Revenue Rise

MT Newswires Live
·
29 Apr

Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion

GuruFocus
·
29 Apr

Incyte’s Mixed Performance and Future Uncertainties Justify Hold Rating

TIPRANKS
·
29 Apr

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

StockStory
·
29 Apr

Incyte: Q1 Earnings Snapshot

Associated Press Finance
·
29 Apr

Incyte Q1 Adj. EPS $1.16 Beats $1.03 Estimate, Sales $1.05B Beat $995.43M Estimate

Benzinga
·
29 Apr

BRIEF-Incyte Q1 Adjusted EPS USD 1.16 Vs. IBES Estimate USD 1.02

Reuters
·
29 Apr

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

THOMSON REUTERS
·
29 Apr

Incyte: Increasing FY25 Jakafi Guidance to New Range of $2,950 - $3,000 Million From $2,925 - $2,975 Million

THOMSON REUTERS
·
29 Apr

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire
·
29 Apr

MORNING BID U.S.-Trade fears ebb, Canada's Carney returns

Reuters
·
29 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
29 Apr

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

StockStory
·
28 Apr

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Business Wire
·
25 Apr

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
24 Apr

Incyte Corp. Stock Rises Wednesday, Still Underperforms Market

Dow Jones
·
24 Apr